Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Incorporating alternative investments into your long-term portfolio can enhance diversification and improve returns.
27,567 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Klarna and Sezzle stand out in the evolving fintech scene, but they offer very different risk/reward profiles. This g...
SpaceX burst onto Nasdaq in June 2026 and has since cooled, but SPCX's size, market reach, and looming index inclusio...
Richtech Robotics faced a sharp pullback in early 2026, driven by execution missteps and market concerns. This piece ...
Bitcoin rides a volatility wave as geopolitics intersect with liquidity cycles. The US appears to be the only market ...
Apple launched the MacBook Neo at a budget price, signaling a potential breakthrough for Mac demand. This article bre...
AMD reported robust Q1 2026 results, with data center revenue surging and strategic AI partnerships signaling a durab...
A surge in investor interest centers on SPCX as SpaceX expands its orbit into launches, satellite networks, and AI ve...
A small AI-focused player claims it helps customers turn modest marketing spend into impressive gains. This piece bre...
A notable $25.7 million position in DNOW signals institutional confidence despite an 18% drop last year. This article...
Tapestry reports a record quarter as Coach powerfully taps Gen Z demand with a Goldilocks mix of luxury and accessibi...
Delinquencies on credit card and auto loan products have climbed to levels not seen since the Great Financial Crisis,...